Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818566 | 0.83 | GBA1 (0.41) | GBA1ATMPDE10ANPC1RAB9A | |
| SCHEMBL18808193 | 0.81 | CCR1 (0.36) | HDAC1ADORA2APDE10AKDM4E | |
| SCHEMBL31169366 | 0.80 | GBA1 (0.36) | GBA1ATMDGAT1PDE10ANPC1 | |
| SCHEMBL1818004 | 0.80 | GBA1 (0.36) | GBA1ATMDGAT1PDE10ANPC1 | |
| SCHEMBL16523823 | 0.80 | HDAC1 (0.36) | HDAC1ADORA2A | |
| SCHEMBL2733260 | 0.80 | HDAC1 (0.36) | HDAC1ADORA2AATMNPC1RAB9A | |
| SCHEMBL1565669 | 0.79 | DGAT1 (0.36) | GBA1DGAT1 | |
| SCHEMBL10272808 | 0.79 | ADORA2A (0.38) | HDAC1ADORA2APDE10ANPC1RAB9A | |
| SCHEMBL30834721 | 0.78 | GBA1 (0.33) | GBA1PDE10ARAB9AKDM4EALDH1A1 | |
| SCHEMBL210170 | 0.76 | HDAC1 (0.35) | HDAC1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593113-B2 | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593113-B2 | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160185776-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185776-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015027021-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-26 | — | — | WO | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | GBA1 864/4885HDAC1 1/4885ADORA2A 4077/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | GBA1 858/4885HDAC1 1/4885ADORA2A 4051/4885 |
| US-20160185776-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | NFKBIA, IKBKB, NFRKB | GBA1 2457/4885HDAC1 192/4885ADORA2A 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.